Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995009 | 1.00 | TSHR (0.48) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL30211265 | 1.00 | TSHR (0.48) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL14928678 | 1.00 | TSHR (0.48) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL25447692 | 0.86 | TSHR (0.47) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL20099923 | 0.86 | TSHR (0.47) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL14292127 | 0.81 | CYP1A2 (0.45) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL13862942 | 0.81 | KCNA5 (0.52) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL13638230 | 0.81 | KCNA5 (0.52) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL10247782 | 0.81 | KCNA5 (0.52) | TSHRCYP1A2CYP3A4KCNA5KCNH2 | |
| SCHEMBL817770 | 0.81 | KCNA5 (0.52) | TSHRCYP1A2CYP3A4KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20210346371-A1 | METHODS OF USING SPLICING MODULATORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20200361915-A1 | SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| US-10745387-B2 | Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| WO-2019199667-A2 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | KEANEY GREGG F (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3514154-A1 | PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190100513-A1 | SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-04-04 | — | — | US | disclosed |
| US-9481669-B2 | Pladienolide pyridine compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-01 | — | — | US | disclosed |
| US-9481669-B2 | Pladienolide pyridine compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | TSHR 4565/4885CYP1A2 3574/4885CYP3A4 3856/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | TSHR 1886/4885CYP1A2 4413/4885CYP3A4 4411/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | TSHR 4772/4885CYP1A2 3702/4885CYP3A4 4033/4885 |
| US-20150329528-A1 | Pladienolide Pyridine Compounds and Methods of Use | PRUNE1, PRDX5, PDCD11 | TSHR 4637/4885CYP1A2 2202/4885CYP3A4 1953/4885 |
| US-20200361915-A1 | SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | SF3B5, SF3B1, SF3A2 | TSHR 4122/4885CYP1A2 2107/4885CYP3A4 1406/4885 |
| US-20190100513-A1 | SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | SF3B5, SF3B1, SF3A2 | TSHR 4122/4885CYP1A2 2107/4885CYP3A4 1406/4885 |
| US-20210346371-A1 | METHODS OF USING SPLICING MODULATORS | SF3B1, RBM17, SF3B5 | TSHR 4220/4885CYP1A2 4814/4885CYP3A4 4683/4885 |
| US-10745387-B2 | Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof | SF3B5, SF3A2, SF3B2 | TSHR 3551/4885CYP1A2 519/4885CYP3A4 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.